GlassScriptPhysician profile
Omer Shahab
NPI 1750739009
$6,384.30
in general payments reported to CMS, 2019-2025
31 companies · $2,462 in 2025
The $2,462 reported for 2025 was more than what 83% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $79.95 · 2021: $113 · 2022: $521 · 2023: $1,246 · 2024: $1,962 · 2025: $2,462.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,906 · Travel and Lodging: $764.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,906.08 |
| Travel and Lodging | $763.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,457.77 | 2022-2025 | Overstitch Endoscopic Suturing System, Exalt Model D, Resolution 360 Clip |
| Abbvie INC. | $1,116.55 | 2022-2025 | Rinvoq, Skyrizi, Linzess |
| Janssen Biotech, INC. | $793.38 | 2020-2025 | Tremfya, Stelara, Simponi |
| Celgene Corporation | $359.67 | 2022-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $248.55 | 2023-2025 | Entyvio, Gattex, Eohilia |
| Qol Medical, LLC | $226.04 | 2024-2025 | Sucraid, Sucraid |
| Medtronic, INC. | $225.86 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $211.05 | 2023-2025 | Xifaxan, Plenvu, Trulance |
| Ardelyx, INC. | $192.48 | 2024-2025 | Ibsrela |
| E.R. Squibb & Sons, L.L.C. | $173.98 | 2023 | Zeposia |
| Intercept Pharmaceuticals, INC. | $152.55 | 2023-2024 | Ocaliva |
| Regeneron Healthcare Solutions, INC. | $139.02 | 2023-2025 | Dupixent |
| Janssen Scientific Affairs, LLC | $121.95 | 2022 | |
| Phathom Pharmaceuticals, INC. | $115.66 | 2024-2025 | Voquezna |
| Gilead Sciences, INC. | $103.55 | 2024-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Steris Corporation | $101.16 | 2022 | |
| Pfizer INC. | $98.54 | 2025 | |
| Exact Sciences Corporation | $73.46 | 2024 | Cologuard Collection Kit |
| Braintree Laboratories, INC. | $70.59 | 2024-2025 | Suflave, Sutab |
| Genzyme Corporation | $67.12 | 2024 | |
| Lilly USA, LLC | $57.91 | 2024-2025 | Omvoh |
| Aimmune Therapeutics, INC. | $47.93 | 2024-2025 | Zenpep |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.44 | 2023-2024 | Cyltezo |
| Caris Mpi, INC. | $34.95 | 2025 | Mi Cancer Seek |
| Capsovision, INC. | $34.60 | 2024 | Capsocam Plus |
| Endogastric Solutions, INC | $27.25 | 2024 | Esophyx |
| Enterra Medical, INC. | $20.78 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $20.42 | 2025 | Iqirvo |
| Cranial Technologies, INC | $17.37 | 2022 | |
| Sandoz INC. | $14.13 | 2025 | |
| Lucid Diagnostics INC. | $13.59 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Omer Shahab listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.